Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EntreMed has announced that the Dana-Farber Cancer Institute has joined the University of Colorado Cancer Center in conducting a Phase I study of ENMD-2076 in advanced cancer patients.
Subscribe to our email newsletter
Safety and tolerability of orally administered ENMD-2076 in refractory cancer patients will be assessed in this Phase I study. A secondary objective for the study will be to determine a dose-dependent response to treatment with ENMD-2076 through the evaluation of pharmacokinetic parameters.
Geoffrey Shapiro, Dana-Farber Cancer Institute, and Wells Messersmith, University of Colorado Cancer Center, will serve as co-principal investigators for the study.
ENMD-2076 is a novel, selective kinase inhibitor with potent activity against Aurora A and tyrosine kinases linked to the promotion of cancer and inflammatory diseases. ENMD-2076 acts through multiple pathways, resulting in both antiproliferative activity and the inhibition of angiogenesis.
James Burns, president & CEO of EntreMed, said: “Our goals for this program over the next twelve months are to complete the clinical trial in solid tumor patients, initiate a clinical trial in patients with hematological cancers, and secure a pharmaceutical partner to help accelerate the development of ENMD-2076.”